You are here

Our science / Clinical Trials / Find a Trial / NCT02778477

Topical Multiple Ascending Dose Study for PF-06423264

Back to Search Print Save as PDF Bookmark Trial

NCT02778477

Last updated on May 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Clinical Research Unit
Brussels, , B-1070 Belgium
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Normal Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy males and female of non-childbearing potential;

- Body Mass Index 17.5-35.5 kg/m2;

- Body weight >50 kg;

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence of history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergises, but excluding untreated, asymptomatic,
seasonal allergies at time of dosing)

NCT02778477
Pfizer
Terminated
Topical Multiple Ascending Dose Study for PF-06423264

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Healthy Volunteers
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
NCT03184168
Males
18+
Years
Madison, Wisconsin
Healthy Volunteers
Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin Pharmacokinetics
NCT03593707
All Genders
18+
Years
Brussels,
Healthy
Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects
NCT03599063
All Genders
18+
Years
New Haven, Connecticut
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
NCT02743871
All Genders
18+
Years
Multiple Sites
Topical Multiple Ascending Dose Study for PF-06423264
A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Doses Of Pf-06423264 Administered Topically To Sequential Cohorts Of Healthy Subjects With And Without Oily Skin
The current study is the first clinical trial proposed with PF-06423264. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of multiple ascending doses of PF-06423264 to healthy adult subjects with or without oily skin.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Normal Healthy
  • Drug: PF-06423264
    Multiple ascending dose of PF-06423264
  • Other: Placebo
    Multiple dose of placebo
    Other Name: Placebo comparator
  • Experimental: Part A_Cohort 1_Active
    Multiple ascending dose of PF-06423264
    Intervention: Drug: PF-06423264
  • Placebo Comparator: Part A_Cohort 1_Placebo
    Multiple dose of placebo
    Intervention: Other: Placebo
  • Experimental: Part A_Cohort 2_Active
    Multiple ascending dose of PF-06423264
    Intervention: Drug: PF-06423264
  • Placebo Comparator: Part A_Cohort 2_Placebo
    Multiple dose of placebo
    Intervention: Other: Placebo
  • Experimental: Part A_Cohort 3_Active
    Multiple ascending dose of PF-06423264
    Intervention: Drug: PF-06423264
  • Placebo Comparator: Part A_Cohort 3_Placebo
    Multiple dose of placebo
    Intervention: Other: Placebo
  • Experimental: Part A_Cohort 4_Active
    Multiple ascending dose of PF-06423264
    Intervention: Drug: PF-06423264
  • Placebo Comparator: Part A_Cohort 4_Placebo
    Multiple dose of placebo
    Intervention: Other: Placebo
  • Experimental: Part A_Cohort 5_Active
    Multiple ascending dose of PF-06423264
    Intervention: Drug: PF-06423264
  • Placebo Comparator: Part A_Cohort 5_Placebo
    Multiple dose of placebo
    Intervention: Other: Placebo
  • Experimental: Part A_Cohort 6_Active
    Multiple ascending dose of PF-06423264
    Intervention: Drug: PF-06423264
  • Placebo Comparator: Part A_Cohort 6_Placebo
    Multiple dose of placebo
    Intervention: Other: Placebo
  • Experimental: Part A_Cohort 7_Active
    Multiple ascending dose of PF-06423264
    Intervention: Drug: PF-06423264
  • Placebo Comparator: Part A_Cohort 7_Placebo
    Multiple ascending dose of placebo
    Intervention: Other: Placebo
  • Experimental: Part B_Cohort 1_Active
    Multiple doses of PF-06423264
    Intervention: Drug: PF-06423264
  • Placebo Comparator: Part B_Cohort 1_Placebo
    Multiple doses of placebo
    Intervention: Other: Placebo
  • Experimental: Part B_Cohort 2_Active
    Multiple doses of PF-06423264
    Intervention: Drug: PF-06423264
  • Placebo Comparator: Part B_Cohort 2_Placebo
    Multiple doses of placebo
    Intervention: Other: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
65
May 23, 2017
May 23, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy males and female of non-childbearing potential;
  • Body Mass Index 17.5-35.5 kg/m2;
  • Body weight >50 kg;

Exclusion Criteria:

  • Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
 
NCT02778477
B7561002
2014-003736-39 ( EudraCT Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now